Chassieu, March 12, 2026 (GLOBE NEWSWIRE) -- Amoéba receives its first order from Koppert and confirms its transformation into a commercial company Chassieu (France), 11 March 2026 – 6:00 pm - Amoéba (FR0011051598 - ALMIB), industrial greentech specialised in the development of natural microbiological solutions based on the patented use of amoebae, announces its first order from its partner Koppert, world leader in biocontrol. Amoéba thus becomes a true commercial company, whose biocontrol activities are no ...

Core Viewpoint - Amoéba is in the final phase of obtaining marketing authorization for its biocontrol product AXPERA in France, with the assessment process led by ANSES, the French Agency for Food, Environmental and Occupational Health & Safety [1][9]. Group 1: Marketing Authorization Process - The marketing authorization application for AXPERA was submitted in March 2025, and France is acting as the rapporteur Member State for the assessment [2]. - The final stage of the assessment includes a comment phase on the draft Registration Report, which is open until March 6, 2026, after which the official marketing authorization will be published [3]. - Amoéba believes there are no obstacles to the marketing authorization, as all requested uses have been deemed acceptable and the product's safety profile confirmed [4]. Group 2: Derogatory Authorizations - Agricultural sectors in France and Italy are seeking exceptional marketing authorizations for AXPERA to address phytosanitary emergencies, similar to the authorization granted in 2025 for use against downy mildew in vineyards [5]. - A new application for exceptional authorization for large-scale trials in the Netherlands has been submitted, allowing AXPERA to be used on multiple crops [6]. - If granted, these derogatory authorizations would enable AXPERA to be marketed for specific uses regardless of the final timetable for standard marketing authorization [7]. Group 3: Company Overview - Founded in 2010, Amoéba specializes in microbiological risk treatment using patented amoebae technology for plant protection and cosmetics [8]. - The company is the only one authorized to use Willaertia amoeba industrially for biocontrol and cosmetic applications, with a focus on the global biocontrol market [10]. - The active substance of AXPERA has been approved in the United States since 2022, and product registration is expected in France in 2026 [11].

Core Insights - Amoéba, a greentech company specializing in natural microbiological solutions, won the gold medal at the SIVAL Innovation 2026 Competition for its biocontrol solution aimed at treating vineyards and vegetable crops, with a commercial launch planned for 2026 pending market authorizations [1][2][3] Company Developments - The AXPERA solution, recognized for its innovative approach to sustainable protection against fungal diseases, will be rebranded as TIAGAN for commercial use in viticulture [2][8] - Amoéba has established a strategic commercial agreement with Koppert, granting exclusive distribution rights for its product in 18 European countries and the United States for five years [4] - The company received the Bernard Blum Gold Medal in October 2025, further solidifying AXPERA's position as a leading biocontrol solution [4] Market Strategy - Amoéba is actively pursuing marketing authorizations for the TIAGAN solution in nine targeted European countries, with decisions expected in the first half of 2026 [7][8] - The company is focusing on building a robust supply chain and ramping up production in preparation for the commercial launch in 2026 [9][10] Industry Recognition - The biocontrol solution has gained significant recognition among industry professionals, particularly for its effectiveness in combating grapevine downy mildew, allowing winegrowers to reduce copper usage [5] - Amoéba was featured in CNN's Innovate series, highlighting its commitment to developing environmentally friendly innovations [6]